Guggenheim on 'Best Idea' Moonlake Immunotherapeutics (MLTX): 'We Continue To Anticipate Highly Positive Pivotal HS Readout Around Sept (2H)'
Tweet Send to a Friend
Guggenheim analyst Yatin Suneja reiterated a Buy rating and $80.00 price target on Moonlake Immunotherapeutics (NASDAQ: MLTX).The analyst comments "Key ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
